Rhelion Life Sciences Corp. (CSE:RHEL)
0.0250
0.00 (0.00%)
Oct 9, 2026, 12:43 PM EST
Rhelion Life Sciences Revenue
Rhelion Life Sciences had revenue of 186.07K CAD in the quarter ending June 30, 2026, a decrease of -66.35%. This brings the company's revenue in the last twelve months to 3.83M, down -2.80% year-over-year. In the fiscal year ending March 31, 2026, Rhelion Life Sciences had annual revenue of 4.20M, down -15.15%. That makes Rhelion Life Sciences the 41,684th largest company in the world by revenue and 811th in Canada.
Revenue (ttm)
3.83M
Revenue Growth
-2.80%
P/S Ratio
4.01
Revenue / Employee
n/a
Employees
n/a
Market Cap
15.35M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 4.20M | -749.01K | -15.15% |
| Mar 31, 2025 | 4.94M | 192.40K | 4.05% |
| Mar 31, 2024 | 4.75M | 802.31K | 20.31% |
| Mar 31, 2023 | 3.95M | 1.62M | 69.84% |
| Mar 31, 2022 | 2.33M | 2.21M | 1,995.96% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Rhelion Life Sciences News
- 1 day ago - Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Licence Agreement with the University of California, San Francisco for a Phase 2 Trial of Psilocybin in Methamphetamine Use Disorder Among People with HIV - Newsfile Corp
- 10 days ago - Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Calgary for Phase 2 Trial of Psilocybin-Assisted Therapy for PTSD in Survivors of Intimate Partner Violence - Newsfile Corp
- 14 days ago - Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resistant Depression in Italy - Newsfile Corp
- 17 days ago - Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New Canadian Patent, Extending the Broadest Natural Psilocybin Patent Estate - Newsfile Corp
- 18 days ago - Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Delivers PEX010 to Bruyere Health Research Institute's Phase 3 Trial of Microdose Psilocybin in Palliative Care - Newsfile Corp
- 22 days ago - Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin - Newsfile Corp
- 24 days ago - Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the University of Southern California for PEX010 in a Trial for Psilocybin-Assisted Mindfulness Therapy - Newsfile Corp
- 25 days ago - Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs - Newsfile Corp